

CHROMEDX LTD.
INTERIM FINANCIAL STATEMENTS
FOR THE PERIOD ENDED MARCH 31, 2014

CHROMEDX LTD.
MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL REPORTING
MARCH 31, 2014

The accompanying condensed interim unaudited financial statements of ChroMedX Ltd. (the "Company") were prepared by management in accordance with International Financial Reporting Standards. Management acknowledges responsibility for the preparation and presentation of the financial statements, including responsibility for significant accounting judgments and estimates and the choice of accounting principles and methods that are appropriate to the Company's circumstances.

Management has established systems of internal control over the financial reporting process, which are designed to provide reasonable assurance that relevant and reliable financial information is produced.

The Director is responsible for ensuring that management fulfills its financial reporting responsibilities and for reviewing and approving the financial statements together with other financial information. The Audit Committee, on behalf of the Director, meets with management to review the internal controls over the financial reporting process, the financial statements together with other financial information of the Company, and the auditor's report. The Audit Committee reports its findings to the Director for its consideration in approving the financial statements for issuance to the shareholders. Management recognizes its responsibility for conducting the Company's affairs in compliance with established financial standards, and applicable laws and regulations, and for maintaining proper standards of conduct for its activities.

Notice of no auditor review of interim financial statements:

Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the interim financial statements they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying interim unaudited financial statements of the Company have been prepared by, and are the responsibility of, the Company's management.

CHROMEDX LTD.**INTERIM STATEMENT OF FINANCIAL POSITION****AS AT**

(Unaudited - in Canadian dollars)

	March 31, 2014	December 31, 2013
ASSETS		
Current		
Cash and cash equivalents	\$ 131	\$ 11,537
Subscription receivable	-	1
GST/HST receivable	1,961	53
	2,092	11,591
Due from Monarch (Note 3)	84,542	16,000
	\$ 86,634	\$ 27,591
LIABILITIES		
Current		
Accounts payable & accrued liability	\$ 6,257	\$ -
Due to related parties (Note 6)	7,236	-
	13,493	-
SHAREHOLDERS' EQUITY (DEFICIENCY)		
Share capital (Note 4)	1	1
Shares to be issued (Note 4)	90,000	28,000
Deficit	(16,860)	(410)
	73,141	27,591
	\$ 86,634	\$ 27,591

Approved on behalf of the board:



Director

The accompanying notes are an integral part of these interim financial statements.

CHROMEDX LTD.**INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)****FOR THE PERIOD ENDED MARCH 31, 2014 AND FROM DECEMBER 3, 2013 to DECEMBER 31, 2013**

(Unaudited - in Canadian dollars)

	Three Months ended March 31, 2014	From December 3, 2013 to December 31, 2013
Expenses		
Operating expenses	\$ 2,802	\$ -
Professional fees	11,148	410
Regulatory fees	2,500	-
Net comprehensive loss for the period	\$ (16,450)	\$ (410)

The accompanying notes are an integral part of these interim financial statements.

CHROMEDX LTD.**INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY)
FOR THE PERIOD ENDED MARCH 31, 2014 (not consistent with income statement)**

(Unaudited - in Canadian dollars)

	Capital Stock		Issuable Capital stock			
	Number of shares	Amount	Number of shares	Amount	Deficit	Total
Balance, December 3, 2013	100	\$ 1	-	\$ -	\$ -	\$ 1
Shares to be issued	-	-	1,400,000	28,000	-	28,000
Net loss for the period	-	-	-	-	(410)	(410)
Balance, December 31, 2013	100	\$ 1	1,400,000	\$ 28,000	\$ (410)	\$ 27,591
Shares issued	-	-	3,100,000	62,000	-	62,000
Net loss for the period	-	-	-	-	(16,450)	(16,450)
Balance, March 31, 2014	100	\$ 1	4,500,000	\$ 90,000	\$ (16,860)	\$ 73,141

The accompanying notes are an integral part of these interim financial statements.

CHROMEDX LTD.
CONDENSED INTERIM STATEMENTS OF CASH FLOWS
FOR THE PERIOD ENDED

(Unaudited - in Canadian dollars)

	Three Months ended March 31, 2014	From December 3, 2013 to December 31, 2013
Cash flows from operating activities		
Net loss for the period	\$ (16,450)	\$ (410)
Changes in non-cash operations working capital		
GST/HST receivable	(1,907)	(53)
Accounts payable and accrued liabilities	6,256	-
Cash flows used in operating activities	<u>(12,101)</u>	<u>(463)</u>
Cash flows from investing activities		
Amounts loaned to intercompany	(68,541)	(16,000)
Cash flows used in investing activities	<u>(68,541)</u>	<u>(16,000)</u>
Cash flows from financing activities		
Issuable common shares	62,000	28,000
Amounts loaned from related party	7,236	-
Cash flows provided by financing activities	<u>69,236</u>	<u>28,000</u>
Net increase (decrease) in cash and cash equivalents	(11,406)	11,537
Cash and cash equivalents, beginning of period	11,537	-
Cash and cash equivalents, end of period	<u>\$ 131</u>	<u>\$ 11,537</u>

The accompanying notes are an integral part of these interim financial statements.

CHROMEDX LTD.**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS****MARCH 31, 2014**

(Unaudited - in Canadian dollars)

1. NATURE OF OPERATIONS AND GOING CONCERN

ChroMedX Ltd. (the "Company") was incorporated and organized under the laws of the Province of Ontario on December 3, 2013. The principal business address of the Company is 365 Bay Street, Suite 400, Toronto, Ontario, M5H 2V1.

The current market conditions and volatility increase the uncertainty of the Company's ability to continue as a going concern as the Company is in the start-up phase of its operation and there is an uncertain ability to raise additional funds. The Company is experiencing, and has experienced, negative operating cash flows and also has negative working capital of \$11,401 as at March 31, 2014. The Company will continue to search for new or alternate sources of financing but anticipates that the current market conditions may impact the ability to source such funds. These material uncertainties may cast significant doubt on the Company's ability to continue as a going concern.

On December 20, 2013, the Company entered into a share exchange agreement with Monarch Energy Limited ("Monarch"). Monarch has agreed to acquire from the Company's shareholders all of the issued and outstanding shares of the Company in exchange for an equal number of common shares in the capital of Monarch. It is expected, and as a condition of completion of the acquisition, that the Company will be the registered holder of certain patents and patents pending in the biomedical technology field. Currently no patents are held by the Company.

2. SIGNIFICANT ACCOUNTING POLICIES**Statement of Compliance**

The interim financial statements have been prepared in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34"), and should be read in conjunction with the Company's most recently prepared audited financial statements for the period ended December 31, 2013.

Basis of Preparation

The financial statements are presented in Canadian dollars, which is the Company's functional and reporting currency.

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities. The estimates and associated assumptions are based on anticipations and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

Financial Instruments

All financial instruments are recorded initially at fair value. In subsequent periods, all financial instruments are measured based on the classification adopted for the financial instrument: held to maturity, loans and receivables, fair value through profit or loss ("FVTPL"), available for sale, FVTPL liabilities or other liabilities.

FVTPL assets and liabilities are subsequently measured at fair value with the change in the fair value recognized in net income (loss) during the period.

Held to maturity assets, loans and receivables, and other liabilities are subsequently measured at amortized cost using the effective interest rate method.

Available for sale assets are subsequently measured at fair value with the changes in fair value recorded in other comprehensive income (loss), except for equity instruments without a quoted market price in an active market and whose fair value cannot be reliably measured, which are measured at cost.

CHROMEDX LTD.**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS****MARCH 31, 2014**

(Unaudited - in Canadian dollars)

The Company has classified its financial instruments as follows:

Financial Instrument	Classification
Cash	FVTPL
Due from Monarch	Amortized cost
Subscription Receivable	Amortized cost
Accounts payable and accrued liabilities	Amortized cost
Due to related parties	Amortized cost

The Company's financial instruments measured at fair value on the balance sheet consist of cash and accrued liabilities. Cash is measured at level 1 of the fair value hierarchy. There are three levels of the fair value hierarchy as follows:

Level 1: Values based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities.

Level 2: Values based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability.

Level 3: Values based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement.

3. DUE FROM MONARCH

During the period, the Company has advanced owing of \$84,542 (December 31, 2013 - \$16,000) to Monarch. The amount is non-interest bearing and without specified terms of repayment.

4. SHARE CAPITAL

On formation, the owner of the Company purchased 100 shares of the company for \$1 per share.

Subsequent to period, investors subscribed for 4,500,000 units of the Company at \$0.02 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder one common share for a period of 24 months following the date of a listing on a recognized Canadian Stock Exchange. \$90,000 have been received on these units prior to period end, and have been reflected as shares to be issued.

Subsequent to March 31, 2014, the Company completed a non-brokered private placement of 5,175,000 units of the Company at \$0.10 per unit. Each unit consists of one common share and one-half common share purchase warrant. Each warrant entitles the holder one common share for a period of 12 months following the date of a listing on a recognized Canadian Stock Exchange.

5. FINANCIAL AND CAPITAL RISK MANAGEMENT

The Company's objective when managing capital is to maintain its ability to continue as a going concern in order to provide returns for its partners and benefits for other stakeholders.

The Company includes shareholder's equity in the definition of capital.

The Company's primary objective with respect to its capital management is to ensure that it has sufficient cash resources to fund its operations. To secure the additional capital necessary to pursue these plans, the Company may attempt to raise additional funds through investments by its shareholders.

Risk Disclosure and Fair Value

The fair value of all the companies' financial instruments approximate fair value due to the short term nature of these instruments. It is management's opinion that the Company is not exposed to significant interest, currency, liquidity or credit risks arising from these financial instruments.

6. RELATED PARTY TRANSACTIONS

Related parties and related party transactions impacting the accompanying financial statements are summarized below and include transactions with the following individuals or entities:

Key management personnel:

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of executive and non-executive members of the Company's Board of Directors and corporate officers.

No amounts were incurred relating to compensation for key management.

As at March 31, 2014, amounts due to related parties consist of \$7,236 (December 31, 2013 - \$Nil) to companies controlled by officers and directors of the Company.

7. EARNINGS PER SHARE

Basic and diluted loss per share for the period end was \$164.50. The weighted average shares outstanding for the quarter was 100 shares.

8. SUBSEQUENT EVENTS

Subsequent to quarter end the Company completed a transaction whereby Monarch acquired of all of the issued and outstanding shares of ChroMedX pursuant to the terms of a share exchange agreement between Monarch, ChroMedX and InvidX Corp. (formerly ChroMedX Inc.) dated December 20, 2013 (as amended by amending agreements dated January 22, 2104, April 16, 2014 and May 6, 2014) (the "Transaction").

As a result of completion of the Transaction, each former ChroMedX shareholder is entitled to receive one (1) Monarch common share, following a 1:20 consolidation of the Monarch common shares, for every one (1) common share of ChroMedX held. This will result in former ChroMedX shareholders acquiring ownership and control of 24,675,100 common shares of Monarch, representing approximately 83% of the issued and outstanding common shares in the capital of Monarch. In addition, an aggregate of 6,675,000 share purchase warrants of ChroMedX remain outstanding following the Transaction and now entitle the holders to acquire Monarch common shares in lieu of ChroMedX common shares based on the same terms and conditions as originally contemplated.